Provided by Tiger Fintech (Singapore) Pte. Ltd.

Myriad Genetics

5.09
+0.17003.46%
Post-market: 5.110.0200+0.39%19:04 EDT
Volume:1.69M
Turnover:8.58M
Market Cap:469.18M
PE:-4.55
High:5.17
Open:4.93
Low:4.93
Close:4.92
Loading ...

Winners And Losers Of Q4: Myriad Genetics (NASDAQ:MYGN) Vs The Rest Of The Therapeutics Stocks

StockStory
·
11 Mar

US$19.13: That's What Analysts Think Myriad Genetics, Inc. (NASDAQ:MYGN) Is Worth After Its Latest Results

Simply Wall St.
·
05 Mar

Myriad Genetics Is Maintained at Neutral by Piper Sandler

Dow Jones
·
05 Mar

Piper Sandler Keeps Their Hold Rating on Myriad Genetics (MYGN)

TIPRANKS
·
04 Mar

Spotting Winners: Sarepta Therapeutics (NASDAQ:SRPT) And Therapeutics Stocks In Q4

StockStory
·
04 Mar

Myriad Genetics Is Maintained at Underperform by B of A Securities

Dow Jones
·
03 Mar

Myriad Genetics Faces Financial Uncertainty Amid Potential Tax Law Changes

TIPRANKS
·
02 Mar

BRIEF-Myriad Genetics And Gabbi To Work Together To Increase Access To Hereditary Cancer Risk Assessment Tools

Reuters
·
28 Feb

Myriad Genetics and Gabbi to Work Together to Increase Access to Hereditary Cancer Risk Assessment Tools

THOMSON REUTERS
·
28 Feb

Myriad Genetics and Gabbi to Work Together to Increase Access to Hereditary Cancer Risk Assessment Tools

GlobeNewswire
·
28 Feb

Here's What Analysts Are Forecasting For Myriad Genetics, Inc. (NASDAQ:MYGN) After Its Yearly Results

Simply Wall St.
·
27 Feb

Myriad Genetics Full Year 2024 Earnings: EPS Misses Expectations

Simply Wall St.
·
26 Feb

Myriad Genetics Faces Cost Restructuring As UnitedHealthcare Ends GeneSight Coverage, Appoints New CEO

Benzinga
·
26 Feb

Why Myriad Genetics (MYGN) Shares Are Plunging Today

StockStory
·
26 Feb

Myriad Genetics Price Target Cut to $19.00/Share From $27.00 by Raymond James

Dow Jones
·
26 Feb

Myriad Genetics Is Maintained at Neutral by UBS

Dow Jones
·
25 Feb

Myriad Genetics, Inc. (MYGN): AI-Driven Precision Medicine for Prostate Cancer

Insider Monkey
·
25 Feb

Stock Track | Myriad Genetics Plummets 25% on Q4 Earnings Decline and Q1 Guidance Miss amid UnitedHealthcare Headwinds

Stock Track
·
25 Feb

UBS Adjusts Price Target on Myriad Genetics to $16 From $18, Maintains Neutral Rating

MT Newswires Live
·
25 Feb

Stock Track | Myriad Genetics Plunges Over 10% on Q1 Guidance Miss, UnitedHealthcare Headwinds

Stock Track
·
25 Feb